You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis

    SBC: DYNUPOL, INC.            Topic: NCI

    Project Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. AutoRegister: A system for enhancing the accuracy of tumor change detection

    SBC: CORTICOMETRICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This project proposes to build an integrated software-based system for enhancing the accuracy of tumor change detection. The intent of the system, called AutoRegister, which is to be deployed on a clinical magnetic resonance imaging (MRI) scanner platform, is to automate the alignment of a patient's brain scan with that of a prior scan, such that subseque ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification

    SBC: VERAQUEL TECHNOLOGIES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes is a particularly debilitating disease and is endemic for a large proportion of the world's population. The unmet challenges in disease management are the lack of long-term efficacy in reducing hyperglycemia and the inability to stop progression. Glucagon-like peptide-1 (GLP-1), a natural gut hormone, provides a platform for therapeutics to ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. High-Purity Peptide Libraries without Chromatographic Separation

    SBC: VERAQUEL TECHNOLOGIES, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The market for peptide and protein products is 30 billion annually and continues to grow. Automated solid phase peptide synthesis (SPPS) is a mainstay of modern medicinal research, and has been used on micromole up tometric ton industrial scale. Peptide drugs such as Exenatide, a GLP-1 analogue and a life-saver to many type-2 diabetes patients, and Fuzeon for ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

    SBC: IQ Medical Imaging LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy (more than 80%) and the third most common cause of death from cancer worldwide. Contrast-enhanced multi-phase multi-detector CT (MDCT) is a routine imaging modality for patients diagnosed with hepatic malignancy. The change of tumor size measured on single-phase (mostly portal-venous p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

    SBC: BESSOR PHARMA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Enhanced recovery of disqualified donor organs using image-guided machine perfusion

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): In the United States alone, 76,000 lives are claimed by liver disease every year. Transplantation is currently the only established treatment, but there is a critical shortage of donor organs. More than 60% of candidates wait over a year to receive a transplant, the majority becoming too ill to tolerate the procedure. These numbers could be improved dramatical ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government